Decrease of cyclic GMP in cerebellar cortex by intrastriatal (--)-sulpiride.
Intraperitoneal administration of (--)-sulpiride (12 to 50 mg/kg) produced a dose-related decrease in cGMP content in cerebellar cortex, while the (+)-sulpiride (10 microgram), but not after intracerebellar injection. These findings support the contention that (--)-sulpiride modifies cerebellar cGMP levels through and action on striatal dopamine receptors.